64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

January 29, 2024

Conditions

Metastatic Prostate Cancer

Interventions

DRUG

64Cu-DOTA-TLX592

TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)

Trial Locations (2)

Envision Medical Imaging, Perth

GenesisCare Wembly, Perth

All Listed Sponsors

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

NCT04726033 - 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) | Biotech Hunter | Biotech Hunter